Metsera Inc. (Ticker: MTSR) is a clinical biopharmaceutical company developing injectable and oral nutrient-stimulated hormone analog peptides to treat obesity, overweight, and related conditions. Their most advanced product candidate, MET-097i, is a monthly, subcutaneously injectable GLP-1 receptor analog that is being developed for the treatment of obesity.

Metsera Inc. will list on January 31, 2025, on NASDAQ. The firm is selling 17.2 million shares at the price range of $15.00-$17.00. The expected Market Capitalization at offer is $1679.04 million. The total offer size is $275.0 million. The offering is managed by BofA Securities/Goldman Sachs/Evercore ISI/Guggenheim Securities/Cantor.